Somerville, MA, United States of America

Chad Cori Huval

This inventor holds 35 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 2 EPO patents, primarily in Biomedical Coatings. Top assignees: Genzyme Corporation, Geltex Pharmaceuticals, Inc., Semprus Biosciences Corporation. Active years: 2000-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chad Cori Huval. Retrieved from https://idiyas.com/inventor/chad-cori-huval

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 35 

% Patents Active = 45.7



Average Co-Inventor Count = 4.6

ph-index = 10

Forward Citations = 271(Granted Patents)


Location History:

  • Grand Coteau, LA (US) (2015)
  • Somerville, MA (US) (2000 - 2018)
  • Cambridge, MA (US) (2013 - 2018)

Company Filing History:


Years Active: 2000-2018

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Non-Fouling Surfaces
Anti-Thrombogenic Grafts
Biomedical Coatings
Amide Dendrimer Compositions
Fat-Binding Polymers
Ionic Polymers
Polyether-Based Sequestrants
Combination Therapy
Hypercholesterolemia
Aryl Boronic Acids
Antimicrobial Coatings
Surface Modification
35 patents (USPTO):Explore Patents

Title: Innovations of Chad Cori Huval in Medical Device Technology

Introduction

Chad Cori Huval, located in Somerville, MA, is a prominent inventor with an impressive portfolio of 35 patents. His work primarily focuses on developing cutting-edge technologies for medical devices, particularly those that enhance biocompatibility and reduce the risk of complications related to biological interactions.

Latest Patents

Among his latest innovations are patents pertaining to non-fouling, anti-microbial, anti-thrombogenic graft compositions. One significant patent outlines a method for preparing articles of manufacture that involve a substrate with a grafted polymer layer designed to maintain a modified surface with minimal fibrinogen adsorption. The details specify that the modified surface achieves a fibrinogen adsorption of less than about 125 ng/cm² in a binding assay conducted under controlled conditions. This innovation shows great promise in reducing the risk of thrombus formation in medical applications.

Additionally, another patent focuses on articles of manufacture such as medical devices that feature a non-fouling surface comprising grafted polymer material, ensuring that biological materials do not adhere to the surface. This advancement has the potential to revolutionize the design of various medical devices, providing both safety and efficiency for patients.

Career Highlights

Chad’s impact on the field is bolstered by his experience working with notable companies including Genzyme Corporation and Geltex Pharmaceuticals, Inc. Through these roles, he has been able to translate his innovative ideas into practical solutions in the medical technology sector.

Collaborations

Collaboration is at the heart of Chad Cori Huval's success as an inventor. He has worked alongside talented professionals, including Stephen Randall Holmes-Farley and Pradeep K Dhal. Their joint efforts reflect a synergy that fosters the growth of inventive solutions in the realm of medical devices.

Conclusion

Chad Cori Huval's dedication and creativity in the field of medical technology are evident through his numerous patents and collaborative endeavors. His focus on developing non-fouling surfaces and anti-thrombogenic materials is paving the way for safer and more effective medical devices, contributing greatly to the healthcare industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…